stockmarketproxy
/
ROIVNasdaq SEC EDGAR

Roivant Sciences Ltd.

Pharmaceutical Preparations·LONDON·FY end 03/31·CIK 1635088
OverviewFinancialsCompensationGovernanceInsidersFilings

Financials

3-year history · USD
MetricFY 2024FY 2023FY 2022Trend
Revenue$29.1M$124.8M$55.3M
Gross Profit————
Operating Income-$1.0B$4.2B-$1.4B
Net Income-$172.0M$4.3B-$845.3M
Operating CF-$839.5M-$765.3M-$677.7M
Capex$4.6M$1.4M$17.4M
Free Cash Flow-$844.0M-$766.6M-$695.2M
Buybacks$1.3B———
Dividends————
Gross Margin————
Operating Margin-3453.3%3399.2%-2444.8%
Net Margin-592.0%3484.9%-1528.9%
FCF Margin-2905.2%-614.3%-1257.4%
R&D / Revenue1894.5%402.0%873.7%
Effective Tax-7.1%0.5%-0.0%
Debt / Equity—0.070.25
Buybacks / FCF-153.2%———

Peer comparison

Pharmaceutical Preparations · 5 peers
CEO Pay Ratio
ROIV
518:1
AXSM
23:1
COGT
95:1
PFE
277:1
ABT
166:1
PTCT
7:1
CEO total comp
ROIV
$163M
AXSM
$34M
COGT
$28M
PFE
$28M
ABT
$24M
PTCT
$23M
Net Margin
ROIV
-592.0%
AXSM
-28.7%
COGT
—
PFE
12.4%
ABT
14.7%
PTCT
39.4%